Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Inositol monophosphatase 1 | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.0215 | 0.0151 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0371 | 0.4663 | 1 |
Echinococcus multilocularis | Bcl 2 ous antagonist:killer | 0.0134 | 0.1321 | 0.1264 |
Mycobacterium tuberculosis | Probable replicative DNA helicase DnaB | 0.0628 | 0.8263 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0215 | 0.0182 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.0215 | 0.0151 |
Chlamydia trachomatis | replicative DNA helicase | 0.0628 | 0.8263 | 1 |
Echinococcus multilocularis | EGFP:Bcl2 fusion protein | 0.0751 | 1 | 1 |
Schistosoma mansoni | apoptosis regulator bax | 0.0134 | 0.1321 | 0.1532 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.0215 | 0.0151 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0045 | 0.0066 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0134 | 0.1321 | 0.6628 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0371 | 0.4663 | 0.5643 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0371 | 0.4663 | 0.5608 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.0215 | 0.079 |
Echinococcus granulosus | Bcl 2 ous antagonist:killer | 0.0134 | 0.1321 | 0.1264 |
Loa Loa (eye worm) | twinkle helicase | 0.0179 | 0.196 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0134 | 0.1321 | 0.1532 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.0215 | 0.0151 |
Schistosoma mansoni | hypothetical protein | 0.0134 | 0.1321 | 0.1532 |
Mycobacterium leprae | PROBABLE REPLICATIVE DNA HELICASE DNAB replicative DNA helicase | 0.0628 | 0.8263 | 1 |
Brugia malayi | Apoptosis regulator proteins, Bcl-2 family protein | 0.0134 | 0.1321 | 1 |
Entamoeba histolytica | myo-inositol monophosphatase, putative | 0.0045 | 0.0066 | 0.5 |
Mycobacterium ulcerans | replicative DNA helicase DnaB | 0.0628 | 0.8263 | 1 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0371 | 0.4663 | 0.5643 |
Leishmania major | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0045 | 0.0066 | 0.5 |
Loa Loa (eye worm) | apoptosis regulator protein | 0.0134 | 0.1321 | 0.6628 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0371 | 0.4663 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | replicative DNA helicase | 0.0628 | 0.8263 | 1 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0371 | 0.4663 | 0.5 |
Schistosoma mansoni | Replicative DNA helicase | 0.0628 | 0.8263 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0134 | 0.1321 | 0.1532 |
Schistosoma mansoni | bcl-2 homologous antagonist/killer (bak) | 0.0134 | 0.1321 | 0.1532 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.0215 | 0.1191 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0215 | 0.0182 |
Treponema pallidum | replicative DNA helicase (dnaB) | 0.0628 | 0.8263 | 0.5 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0045 | 0.0066 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.0371 | 0.4663 | 1 |
Trypanosoma brucei | inositol-1(or 4)-monophosphatase 1, putative | 0.0045 | 0.0066 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0371 | 0.4663 | 0.5608 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0215 | 0.0182 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 5.0119 um | PUBCHEM_BIOASSAY: qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 7.0795 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 13.1154 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 89.1251 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.